Decision Support Systems and Closed‐Loop

Mastrototaro JJ . The MiniMed continuous glucose monitoring system. Diabetes Technol Ther, 2000; 2(Suppl 1): S13–S18.

Feldman B , Brazg R , Schwartz S , Weinstein R . A continuous glucose sensor based on wired enzyme technology – results from a 3-day trial in patients with type 1 diabetes. Diabetes Technol Ther, 2003; 5: 769–778.

Deiss D , Bolinder J , Riveline J , et al. Improved glycemic control in poorly controlled patients with type 1 diabetes using real-time continuous glucose monitoring. Diabetes Care, 2006; 29: 2730–2732.

Garg K , Zisser H , Schwartz S , et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor. Diabetes Care, 2006; 29: 44–50.

Kovatchev BP , Clarke WL . Continuous glucose monitoring reduces risks for hypo- and hyperglycemia and glucose variability in diabetes. Diabetes, 2007; 56 (Suppl 1): 0086OR.

The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med, 2008; 359: 1464–1476.

Klonoff DC . Continuous glucose monitoring: Roadmap for 21st century diabetes therapy. Diabetes Care, 2005; 28: 1231–1239.

Hovorka R . Continuous glucose monitoring and closed-loop systems. Diabet Med, 2006; 23: 1–12.

Klonoff DC . The artificial pancreas: How sweet engineering will solve bitter problems. J Diabetes Sci Technol, 2007; 1: 72–81.

Buckingham B , Cobry E , Clinton P , et al. Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Technol Ther, 2009; 11: 93–97.

Clarke W , Kovatchev B . Statistical tools to analyze continuous glucose monitor data. Diabetes Technol Ther, 2009; 11(Suppl 1): S45–54.

Bergenstal R. Understanding continuous glucose monitoring data. In: Role of Continuous Glucose Monitoring in diabetes treatment, American Diabetes Association. Arlington, VA; 2018.

Nimri R , Piper M , Pinsker JE , Dassau E . Decision support systems and closed loop. Diabetes Technol Ther, 2020; 22(Suppl 1): S47–S62.

Nimri R . Decision Support systems for insulin treatment adjustment in people with type 1 diabetes. Pediatr Endocrinol Rev, 2020; 17(Suppl 1): 170–182.

Nimri R , Kovatchev B , Phillip M . Decision support systems and closed-loop. Diabetes Technol Ther, 2021; 23(Suppl 2): S69–S84.

Johnson ML , Martens TW , Criego AB , Carlson AL , Simonson GD , Bergenstal RM . Utilizing the ambulatory glucose profile to standardize and implement continuous glucose monitoring in clinical practice. Diabetes Technol Ther, 2019; 21(Suppl 2): S217–S225.

Woldaregay AZ , Årsand E , Botsis T , Albers D , Mamykina L , Hartvigsen G . Data-driven blood glucose pattern classification and anomalies detection: Machine-learning applications in type 1 diabetes. J Med Internet Res, 2019; 21: e11030.

Woldaregay AZ , Årsand E , Walderhaug S , Albers D , Mamykina L , Botsis T , Hartvigsen G . Data-driven modeling and prediction of blood glucose dynamics: Machine learning applications in type 1 diabetes. Artif Intell Med, 2019; 98: 109–134.

Augstein P , Heinke P , Vogt L , et al. Q-Score: Development of a new metric for continuous glucose monitoring that enables stratification of antihyperglycaemic therapies. BMC Endocr Disord, 2015; 15: 22.

Spänig S , Emberger-Klein A , Sowa JP , Canbay A , Menrad K , Heider D . The virtual doctor: An interactive clinical-decision-support system based on deep learning for non-invasive prediction of diabetes. Artif Intell Med, 2019; 100: 101706.

Tyler NS , Mosquera-Lopez CM , Wilson LM , et al. An artificial intelligence decision support system for the management of type 1 diabetes. Nat Metab, 2020; 2: 612–619.

Weisman A , Bai JW , Cardinez M , Kramer CK , Perkins BA . Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: A systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol, 2017; 5: 501–512.

Kovatchev BP . The artificial pancreas in 2017: The year of transition from research to clinical practice. Nat Rev Endocrinol, 2018; 14: 74–76.

Bekiari E , Kitsios K , Thabit H , et al. Artificial pancreas treatment for outpatients with type 1 diabetes: Systematic review and meta-analysis. BMJ, 2018; 361: k1310.

Karageorgiou V , Papaioannou TG , Bellos I , et al. Effectiveness of artificial pancreas in the non-adult population: A systematic review and network meta-analysis. Metabolism, 2019; 90: 20–30.

Kovatchev BP , Anderson SM , Raghinaru D , et al. Randomized Controlled Trial of Mobile Closed-Loop Control. Diabetes Care, 2020; 43: 607–615.

Tauschmann M , Thabit H , Bally L , et al. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: A multicentre, 12-week randomised trial. Lancet, 2018; 392: 1321–1329.

Benhamou PY , Franc S , Reznik Y , et al. Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: A 12-week multicentre, open-label randomised controlled crossover trial. Lancet Digital Health, 2019; 1: e17–25.

Brown SA , Kovatchev BP , Raghinaru D , et al., for the iDCL Trial Research Group. Six-month randomized multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med, 2019; 381: 1707–1717.

U.S. Food & Drug Administration: FDA authorizes first interoperable, automated insulin dosing controller designed to allow more choices for patients looking to customize their individual diabetes management device system. https:// www.fda.gov/news-events/press-announcements/fda-authorizes-first-interoperable-automated-insulin-dosing-controller-designed-allow-more-choices.

Lal RA , Basina M , Maahs DM , Hood K , Buckingham B , Wilson DM . One year clinical experience of the first commercial hybrid closed-loop system. Diabetes Care, 2019; 42: 2190–2196.

Akturk HK , Giordano D , Champakanath A , Brackett S , Garg S , Snell-Bergeon J . Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes. Diabetes Obes Metab, 2020; 22: 583–589.

Beato-Víbora PI , Gallego-Gamero F , Ambrojo-López A , Gil-Poch E , Martín-Romo I , Arroyo-Díez FJ . Rapid improvement in time in range after the implementation of an advanced hybrid closed-loop system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther, 2021; 23: 609–615.

Cobry EC , Hamburger E , Jaser SS . Impact of the hybrid closed-loop system on sleep and quality of life in youth with type 1 diabetes and their parents. Diabetes Technol Ther, 2020; 22: 794–800.

Berget C , Messer LH , Vigers T , et al. Six months of hybrid closed loop in the real-world: An evaluation of children and young adults using the 670G system. Pediatr Diabetes, 2020; 21: 310–318.

Messer LH , Berget C , Vigers T , et al. Real world hybrid closed-loop discontinuation: Predictors and perceptions of youth discontinuing the 670G system in the first 6 months. Pediatr Diabetes, 2020; 21: 319–327.

Atlas E , Nimri R , Miller S , Grunberg EA , Phillip M . MD-logic artificial pancreas system: A pilot study in adults with type 1 diabetes. Diabetes Care, 2010; 33: 1072–1076.

Battelino T , Danne T , Bergenstal RM , et al. Clinical targets for continuous glucose monitoring data interpretations: Recommendations from the International Consensus on Time in Range. Diabetes Care, 2019; 42: 1593–1603.

Bergenstal RM , Nimri R , Beck RW , et al. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): A multicentre, randomised, crossover trial. Lancet, 2021; 397: 208–219.

Cobelli C , Renard E , Kovatchev BP , et al. Pilot studies of wearable outpatient artificial pancreas in type 1 diabetes. Diabetes Care, 2012; 35: e65–e67.

Breton MD , Kanapka LG , Beck RW , et al. A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med, 2020; 383: 836–845.

Bergenstal RM , Beck RW , Close KL , et al. Glucose management indicator (GMI): A new term for estimating A1C from continuous glucose monitoring. Diabetes Care, 2018; 41: 2275–2280.

Breton MD , Kovatchev BP . One year real-world use of the control-IQ advanced hybrid closed-loop technology. Diabetes Technol Ther, 2021; 23: 601–608.

Dovc K , Piona C , Yeşiltepe Mutlu G , et al. Faster compared with standard insulin aspart during day-and-night fully closed-loop insulin therapy in type 1 diabetes: A double-blind randomized crossover trial. Diabetes Care, 2020; 43: 29–36.

Boughton CK , Hartnell S , Thabit H , et al. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study. Diabetes Obes Metab, 2021; 23: 1389–1396.

El-Khatib FH , Russell SJ , Nathan DM , Sutherlin RG , Damiano ER . A bihormonal closed-loop artificial pancreas for type 1 diabetes. Science Transl Med, 2010; 2: 27ra27.

Castellanos LE , Balliro CA , Sherwood JS , et al. Performance of the insulin-only iLet bionic pancreas and the bihormonal iLet using dasiglucagon in adults with type 1 diabetes in a home-use setting. Diabetes Care, 2021; 44: e118–e120.

Rao L , Ren C , Luo S , Huang C , Li X . Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: Meta-analysis of randomized controlled trials. Acta Diabetol, 2021; 58: 869–880.

Danne T , Garg S , Peters AL , et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care, 2019; 42: 1147–1154.

Singh S , Rushakoff RJ , Neinstein AB . A case report of diabetic ketoacidosis with combined use of a sodium glucose transporter 2 inhibitor and hybrid closed-loop insulin delivery. J Diabetes Sci Technol, 2019; 13: 605–606.

Kudva YC , Carter RE , Cobelli C , Basu R , Basu A . Closed-loop artificial pancreas systems: Physiological input to enhance next-generation devices. Diabetes Care, 2014; 37: 1184–1190.

Zaharieva DP , Messer LH , Paldus B , O'Neal DN , Maahs DM , Riddell MC . Glucose control during physical activity and exercise using closed loop technology in adults and adolescents with type 1 diabetes. Can J Diabetes, 2020; 44: 740–749.

DeBoer MD , Cherñavvsky DR , Topchyan K , Kovatchev BP , Francis GL , Breton MD . Heart rate informed artificial pancreas system enhances glycemic control during exercise in adolescents with T1D. Pediatr Diabetes, 2017; 18: 540–546.

Jacobs PG , Resalat N , El Youssef J , et al. Incorporating an exercise detection, grading, and hormone dosing algorithm into the artificial pancreas using accelerometry and heart rate. J Diabetes Sci Technol, 2015; 9: 1175–1184.

Castle JR , El Youssef J , Wilson LM , et al. Randomized outpatient trial of single- and dual-hormone closed-loop systems that adapt to exercise using wearable sensors. Diabetes Care, 2018; 41: 1471–1477.

Jacobs PG , El Youssef J , Reddy R , et al. Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy. Diabetes Obes Metab, 2016; 18: 1110–1119.

Battelino T , Danne T , Bergenstal RM , et al. Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the International Consensus on Time in Range. Diabetes Care, 2019; 42: 1593–1603.